Related Experiment Videos
Effect of YM294, recombinant human interleukin-11, on carboplatin-induced thrombocytopenia in rats
1Clinical Pharmacology Research Laboratories, Institute for Drug Development Research, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan.
Abstract:
We investigated the effects of YM294, recombinant human interleukin-11, on changes in blood cell levels in carboplatin-treated rats. Continuous infusion of YM294 was carried out by either intravenous or subcutaneous injection (10 and 100 micrograms/rat/day) for 14 days via an implanted osmotic pump. Carboplatin (30 mg/kg iv) significantly decreased platelet counts on days 7-9; counts subsequently increased to levels greater than the initial level by day 21. Intravenous administration of YM294 inhibited this decrease in platelet count by carboplatin and increased the platelet count in the recovery phase in a dose-dependent manner. YM294 also showed effects on carboplatin-induced changes in white blood cell and red blood cell counts; these effects seemed, however, to be neither consistent nor dose-dependent. The effects of YM294 on subcutaneous infusion were similar to those on intravenous infusion. The effect of YM294 on the survival of rats treated with a higher dose of carboplatin (60 mg/kg iv) was also investigated. YM294 (100 micrograms/rat/day) given by continuous intravenous infusion increased the 30-day survival rate. These results confirm the utility of YM294 in the treatment of thrombocytopenia after chemotherapy.
Insights
Recombinant human interleukin-11 (YM294) effectively prevents chemotherapy-induced thrombocytopenia in rats. YM294 also improves survival rates when combined with higher carboplatin doses.
Area of Science:
- Hematology
- Pharmacology
- Oncology
Background:
- Carboplatin chemotherapy can cause significant thrombocytopenia, a condition characterized by low platelet counts.
- Recombinant human interleukin-11 (rhIL-11) is a cytokine with demonstrated effects on hematopoiesis.
- The potential of rhIL-11 to mitigate chemotherapy-induced side effects warrants investigation.
Purpose of the Study:
- To evaluate the efficacy of YM294 (rhIL-11) in preventing and treating thrombocytopenia in a rat model of carboplatin chemotherapy.
- To assess the impact of YM294 on other blood cell lineages and the survival rate of rats undergoing carboplatin treatment.
Main Methods:
- Rats were treated with carboplatin (30 mg/kg or 60 mg/kg intravenously).
- YM294 was administered via continuous intravenous or subcutaneous infusion (10 and 100 µg/rat/day) for 14 days using osmotic pumps.
- Blood cell counts (platelets, white blood cells, red blood cells) and survival rates were monitored.
Main Results:
- Carboplatin significantly reduced platelet counts, which YM294 administration inhibited in a dose-dependent manner.
- YM294 enhanced platelet recovery and increased overall survival rates in rats treated with a higher carboplatin dose.
- Effects on white blood cell and red blood cell counts were inconsistent and not dose-dependent.
Conclusions:
- YM294 demonstrates significant efficacy in preventing and treating carboplatin-induced thrombocytopenia.
- Continuous infusion of YM294 improves platelet levels and survival outcomes in chemotherapy-treated rats.
- YM294 shows promise as a supportive therapy to manage hematological toxicities associated with carboplatin chemotherapy.